Saturday - September 19, 2026
AstraZeneca: Efzimfotase Alfa Granted Priority Review in the U.S. as Treatment for Patients With Hypophosphatasia Aged 2 Years and Older
September 19, 2026
WILMINGTON, Delaware, Sept. 19 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older

18 September 2026

Based on results from the largest Phase III clinical program in HPP including

HICKORY, MULBERRY and CHESTNUT trials

If approved, efzimfotase alfa will be the first t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products